Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a single-center study investigating outcomes of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who were in complete metabolic response before axicabtagene ciloleucel (axi-cel) infusion, compared to those who were not in complete metabolic response. Results showed improved outcomes and a lower adverse event rate for the patients in complete metabolic response prior to CAR-T infusion. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.